Ojjaara (momelotinib) approved in Canada for the treatment of ...
1 day ago · Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients who have moderate to severe anemia and other key manifestations associated with the disease.; This approval underscores GSK’s commitment to help drive progress for people living with complex blood cancers. MISSISAUGA, ON - GSK announced today that Health Canada has approved ...
Health Canada approves GSK's Ojjaara for myelofibrosis in …
2 hours ago · November 13, 2024. GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is indicated ...
GSK pays Flagship biotech $80M for preclinical neuro pact
1 day ago · GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks. GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Vesalius Announces Multi-Target Strategic Alliance with GSK to …
1 day ago · GSK will control all development and commercialization. Vesalius will receive $80 million in upfront and equity payments, and is eligible to receive potential preclinical, ...
OJJAARA | GSK Canada
Registered in England and Wales No. 3888792. GlaxoSmithKline Inc. 100 Milverton Drive, Suite 800, Mississauga, ON L5R 4H1. > GSK Modern Slavery Act Statement 2023 (PDF - 154.2KB) GSK websites. GSK Global website. Market website selector. Global Behind the science magazine. GSKPro for healthcare professionals.
GSK China scandal - Wikipedia
The GSK China scandal in 2013 resulted from bribes made by GSK China, a division of multinational pharmaceutical company GlaxoSmithKline ... GSK's Lamivudine was priced at 142 RMB in mainland China, while it only cost 18RMB, 26RMB, 30RMB to buy the drug in Korea, Canada and Britain respectively. Adefovir Dipivoxil, another product of GSK, was ...
GSK Steps Up Parkinson’s Focus With US Biotech Deal
1 day ago · Listen. 1:49. GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease. GSK will pay $80 ...
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite ...
Oct 12, 2021 · In CheckMate 142, median PFS was not reached across patient subgroups by BRAF or KRAS mutation status after a minimum follow-up of 24.2 months of treatment with 1L nivolumab plus low-dose ipilimumab. A substantial number of patients (29%) treated with 1L pembrolizumab monotherapy had PD as best response.
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite ...
Oct 12, 2021 · First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. JCO 40 , 161-170 (2022). DOI: 10.1200/JCO.21.01015
Statement: Zantac (ranitidine) litigation – settlement ... - GSK
Oct 9, 2024 · GSK also confirms that it has reached an agreement in principle to pay a total of $70 million to resolve the Zantac qui tam complaint previously filed by Valisure. The agreement in principle is subject to final approval from the Department of Justice (the “ Qui Tam Settlement”). GSK has not admitted any liability in the State Courts ...